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Abstract: There are currently a number of antiretroviral drugs that have been approved by 
the Food and Drug Administration for use in the treatment of human immunodeficiency virus 
(HIV). More recently, antiretrovirals are being evaluated in the clinic for prevention of HIV 
infection. Due to the challenging nature of treatment and prevention of this disease, the use 
of nanocarriers to achieve more efficient delivery of antiretroviral drugs has been studied. 
Various forms of nanocarriers, such as nanoparticles (polymeric, inorganic, and solid lipid), 
liposomes, polymeric micelles, dendrimers, cyclodextrins, and cell-based nanoformulations 
have been studied for delivery of drugs intended for HIV prevention or therapy. The aim of 
this review is to provide a summary of the application of nanocarrier systems to the delivery 
of anti-HIV drugs, specifically antiretrovirals. For anti-HIV drugs to be effective, adequate 
distribution to specific sites in the body must be achieved, and effective drug concentrations 
must be maintained at those sites for the required period of time. Nanocarriers provide a means 
to overcome cellular and anatomical barriers to drug delivery. Their application in the area of 
HIV prevention and therapy may lead to the development of more effective drug products for 
combating this pandemic disease.
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Introduction
Human retroviruses are of four major types, ie, human T cell leukemia viruses, 
HTLV-1, HTLV-2, and human immunodeficiency viruses, HIV-1 and HIV-2. HTLV-1 
and HTLV-2 belong to the subclass of oncovirinae and cause adult T cell leukemia and 
spastic paraparesis. HIV-1 and HIV-2 from the subclass lentivirinae are responsible 
for causing acquired immunodeficiency syndrome (AIDS). All of these viruses infect 
CD4 receptor-bearing T cells. HIV-1 is the most pathogenic virus of these four types, 
and is mainly responsible for the global AIDS pandemic. HIV infection is spread by 
the transfer of body fluids due to blood transfusion, organ transplant, sexual contact, 
or perinatally from mother to offspring. Currently, more than 33 million people are 
HIV-positive, substantiating the pathogenesis of this disease.1 Over the past 25 years, 
there has been an extensive amount of research conducted to understand the patho-
genesis of the infection and for the development of prevention methods and treatment 
strategies.
Sexual transmission of HIV occurs at the mucosal surface. The female genital tract 
is the primary route of heterosexual HIV transmission.2,3 Sexual transmission of HIV 
by the rectal route is also a major problem, given that the physiology of the rectum 
makes it more susceptible to infection.4 Immune cells, ie, T cells, macrophages, and International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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dendritic cells are the primary targets for HIV infection. In 
females, these are present in the subepithelial layers of the 
vaginal and cervical mucosa.5 HIV transmitted during sexual 
intercourse by semen or other biological fluids penetrates the 
stratified squamous epithelium of the vagina and the ectocer-
vix or the columnar epithelium of the endocervix to infect 
the target cells. Several mechanisms have been proposed 
for the in vivo transmission of HIV , including direct infec-
tion of the   epithelial cells, transcytosis through the epithelial 
cells, epithelial transmigration, uptake by intraepithelial 
Langerhans cells, and migration through physical breaches in 
the epithelium.6,7 However, the mechanisms involved in the 
sexual transmission of HIV have yet to be fully elucidated.
HIV primarily infects cells of the immune system and 
central nervous system (CNS). The first step in the   infection 
cycle of HIV is fusion of the viral envelope with the target cell 
and subsequent release of its genome into the cell. Sequential 
interactions of the HIV envelope glycoproteins, gp120 and 
gp41, with CD4 receptors, followed by interactions with 
CCR5 or CXCR4 coreceptors, initiate HIV target cell 
fusion.8 Several studies have been reported suggesting an 
alternative endocytotic mechanism of HIV entry. Fusion of 
HIV with endosomes and micropinosomes has been observed 
by electron microscopy.9,10 Augmentation of HIV infection 
by blocking endosomal acidification11 and its reduction 
by inhibition of clathrin-mediated endocytosis12 support 
the existence of an endocytotic mechanism of HIV entry. 
Recently, Miyauchi et al reported the occurrence of complete 
HIV-1 fusion with cells in the endosomes of the epithelial 
and lymphoid cells via dynamin-dependent mechanisms.13 
According to these studies, HIV enters cells via endocytosis 
at the cell membrane. Subsequently, the infectious HIV fuses 
with an endosome but not with the plasma membrane. Once 
fusion of the HIV membrane with the host cell occurs, the 
viral RNA genome is released into the cell where it undergoes 
reverse transcription followed by integration of the proviral 
DNA into the host chromosome. Subsequent to translation, 
immature viral particles egress the cell by assembly of the 
viral proteins at the cell membrane. Structural rearrangement 
subsequent to virion budding generates a mature virus that 
can infect other cells.
Antiretroviral drugs for the treatment of retroviral 
  infections, primarily HIV , are of different categories based 
on the stage of the HIV life cycle that they act on. Reverse 
transcriptase inhibitors act by blocking the activity of the 
reverse transcriptase enzyme, thus preventing the   construction 
of viral DNA. Nucleoside analog reverse transcriptase inhibi-
tors, including zidovudine, lamivudine, stavudine, abacavir, 
  emtricitabine, zalcitabine,   dideoxycytidine,   dideoxynosine, 
tinofovir disoproxil fumarate, and didanosine act by 
  incorporation into the viral DNA leading to chain   termination, 
whereas nonnucleoside analog reverse transcriptase 
  inhibitors, including etravirine, delavirdine, efavirenz, and 
nevirapine block the binding potential of the reverse tran-
scriptase enzyme. Protease inhibitors including ritonavir, 
saquinavir, lopinavir, indinavir, amprenavir, fosamprenavir, 
darunavir, atazanavir, nelfinavir, and tipranavir interfere with 
viral assembly by blocking the protease enzyme necessary for 
cleaving the nascent viral proteins for final assembly into new 
virions. Fusion inhibitors (enfuvirtide) block the fusion of the 
virus with the cell membrane and subsequent entry into the 
host cells. Integrase inhibitors (raltegravir) block the integra-
tion of viral DNA into the host cell DNA. Entry inhibitors 
(maraviroc) bind to CCR5, a coreceptor on the viral membrane 
surface used in the entry of the virus into the host cell.
Antiretroviral therapy (ART) using any single class of 
drugs has not been efficient in controlling infection and 
disease progression due to the development of resistant 
strains of the virus. Hence, three or more drugs are used in 
combination, known as highly effective antiretroviral therapy 
(HAART), to minimize the development of resistant strains 
by attacking the viral infection more aggressively. HAART 
has been able to reduce the mortality due to HIV infection 
significantly and increase the life expectancy of infected 
individuals.14 The median survival of HIV-positive patients 
has been increased from less than a year to about 10 years 
due to HAART.15 However, HAART has not been a complete 
solution to the problem. Disease management is challeng-
ing due to several factors, such as development of multiple 
resistant strains, presence of viral reservoir sites that are 
inaccessible to the existing drug delivery methods, latent cells 
with integrated HIV DNA which are susceptible to in vivo 
activation at a later stage, reduced patient compliance due 
to increased side effects, and toxicity as a result of the high 
and frequent   dosing involved. The high cost associated with 
HAART is also an important issue, especially in developing 
nations where HIV prevalence is high.15
Propagation of the HIV virus occurs at the cellular and 
molecular level and is regulated by several enzymes and 
biochemical processes. Hence, for anti-HIV drugs to be more 
effective, adequate extra- and intracellular distribution is 
  necessary for sufficient duration of action at the target sites. 
From a drug delivery standpoint, focus areas can be catego-
rized as ART for prevention of infection (as in sexual trans-
mission), ART for eradicating the virus from the circulation, 
and ART for removal of the virus from the sanctuary sites.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Antiretroviral agents that disrupt the viral membrane 
before attachment of the virus to the host cell can be deliv-
ered to the vaginal/rectal lumen without deeper penetration 
into the mucosa. Once the viral membrane is destroyed, the 
viral genome of the virus loses its infectivity. Such delivery 
systems may aid in the prevention of infection. Drug delivery 
systems that can deliver antiretrovirals to the subepithelial 
layers, as well as penetrate the target cells to release their 
drug intracellularly, may help in eradication of the virus from 
infected cells and prevent further infection. These are prefer-
able because they improve the efficacy of the antiretrovirals 
by ensuring sufficiently high drug concentrations at the target 
site of action. Delivery systems that can deliver and maintain 
therapeutic concentrations of the drug in the systemic cir-
culation are useful to reduce and/or eliminate the viral load 
and treat HIV infection. Targeted delivery systems that can 
cross the physiological barriers and deliver their payload to 
the viral sanctuary sites, such as the CNS, lymphatic system, 
and macrophages intracellularly are useful in eradicating the 
virus and treatment of HIV infection.
The reservoir sites for HIV are categorized as cellular and 
anatomical sites, based on the impediments to eliminating 
the viruses.16 CD4+ T lymphocytes, macrophages, and fol-
licular dendritic cells constitute cellular reservoirs because 
the virus exists in a physical state capable of surviving for 
prolonged periods despite otherwise therapeutic levels of 
antiretroviral agents.16 These sites are not very accessible 
to antiretroviral drugs per se due to the presence of efflux 
proteins such as P-glycoprotein and multidrug resistance 
protein on the cell surface preventing the drugs from attaining 
therapeutic concentrations intracellularly. The CNS, lym-
phatic system, lungs, and genital organs constitute anatomical 
sanctuary sites for the virus, because attaining antiretroviral 
drug concentrations within the respective anatomic spaces 
is the limiting factor due to the presence of barriers, such 
as the blood-brain barrier (BBB), blood-cerebrospinal fluid 
barrier, and blood-testes barrier.16 Drug delivery systems 
that can deliver therapeutic concentrations of antiretroviral 
drugs preferentially to these viral sanctuary sites are being 
investigated to overcome the problems mentioned.
Nanocarriers provide an option for the optimization of 
drug delivery to the target sites in the body. They can poten-
tially be engineered to deliver antiretroviral drugs preferen-
tially to target sites, with limited or poor distribution to the 
nontarget sites. The resulting alteration in pharmacokinetics 
and biodistribution of the antiretrovirals may increase their 
efficacy and reduce the toxicity both during prevention and 
treatment of infection.
Nanocarrier drug delivery systems
Nanocarriers constitute a versatile drug delivery system, due 
to their ability to overcome physiologic barriers and guide the 
drug to specific cells or intracellular compartments either by 
passive or ligand-mediated targeting mechanisms. This is due 
to their small size, typically in the 10–1000 nm range. Entry 
of nanocarriers into the cells can occur via energy-dependent 
or -independent mechanisms, such as endocytosis, pinocy-
tosis, fluid-phase diffusion, receptor-mediated transport, or 
facilitated transport.17 Endocytosis and receptor-mediated 
transport are the primary mechanisms of intracellular uptake 
of nanocarriers.18 Nanocarriers can be classified according to 
the material used for their manufacture, such as liposomes, 
dendrimers, polymeric nanoparticles, solid lipid nanopar-
ticles, and metal nanoparticles. They are also classified as 
nanospheres, nanocapsules, or nanoparticles based upon the 
dispersion of drug within the nanocarrier.
Nanocarriers offer several advantages, such as the 
  protection of drugs against degradation,17,19 targeting of drugs 
to specific sites of action,20,21 and delivery of biologic mol-
ecules, such as proteins,22 peptides,23 and oligonucleotides.24,25 
  Nanocarriers are currently being investigated for many 
therapeutic applications to overcome typical drug delivery 
challenges, such as conformational stability,   physicochemical 
stability,21 enhanced cellular uptake of poorly permeable 
drugs,21,26 reduced cellular and tissue clearance of drugs,21 
sustained drug delivery,27 and reduction of immunogenic 
response.17 The therapeutic efficacy and safety of drugs can 
be significantly improved by targeted delivery using nano-
carriers. A target site may have several specific attributes 
that can be targeted by either single or multicomponent 
targeting moieties. Ligands such as transferrin, thiamine, 
and cell-  penetrating peptides, such as HIV-1 transactivating 
transcriptional activator peptide, are some of the most com-
mon targeting moieties used to overcome the CNS barriers 
to drug delivery. The use of multiple targeting moieties in a 
nanocarrier system may improve their efficiency in terms of 
site specificity.28 However, incorporation of multiple targeting 
moieties into a single nanocarrier increases the complexity of 
the formulation processing required, which may result in lower 
yield, higher production cost, and scale-up difficulties.
The small size of the nanocarriers enables them to be 
transported more easily through barriers, such as mucus 
and mucosal epithelium, by passive or active transport 
mechanisms.18 It is their size that allows them to penetrate 
through cells and deliver drugs intracellularly without   risking 
extracellular degradation. However, the smaller the size of 
the nanocarrier, the harder it is to control the drug release International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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kinetics from the nanocarrier. Drug diffuses out of smaller 
  nanocarriers faster, resulting in burst effects and an inability 
to obtain sustained or controlled drug delivery over prolonged 
periods of time.29,30 The drug release kinetics can be improved 
by increasing the size of the nanocarriers, which results in 
higher drug loading and prolonged drug release with a lower 
burst effect.31,32 However, increasing nanocarrier size may lead 
to their hindered transport across membranes.   Optimization of 
particle size with desired release characteristics is a challenge 
with nanocarrier drug delivery systems.
There are several additional challenges with respect to 
nanocarrier formulations. Due to the small size of nanocar-
riers, their higher surface area compared with micro- and 
macrosystems provides a high surface energy which can 
result in stability issues, such as aggregation.17,33 Nanocarriers 
have an extremely limited drug reservoir volume due to their 
high surface to volume ratios. In addition, the conventionally 
low entrapment efficiencies obtained for nanocarriers reduces 
the amount of drug that can actually be loaded.29 A significant 
amount of drug may also be lost during loading due to the 
nature of the processes involved in nanocarrier production.
Nevertheless, the benefits associated with nanocarriers 
for antiretroviral drug delivery far outweigh their chal-
lenges. A significant amount of research has been conducted 
to overcome the challenges associated with nanocarrier-
mediated drug delivery with varying degrees of success. 
Although several reviews are available on this topic,15,21,34–39 
this review provides a cumulative overview of the many dif-
ferent applications of nanotechnologies specific to their use 
for delivery of antiretroviral drugs in HIV prevention and 
therapy. Different types and modifications of nanocarriers 
have been studied for improved delivery of antiretroviral 
drugs. These are discussed in the following sections.
Nanotechnology for antiretroviral 
drug delivery
Polymeric nanoparticles
Synthetic and semisynthetic polymers have attracted great 
attention for nanotechnology-based drug delivery due 
to several desirable features, including manufacturing 
reproducibility, stability, and sustained drug release. 
Different materials have been employed in the preparation 
of nanoparticles, and material choice in some cases is 
driven by application. Synthetic or semisynthetic polymers, 
such as poly(lactic acid) (PLA), poly(lactic-co-glycolic 
acid) (PLGA), poly(alkyl)cynoacrylates, poly(ethylene 
  glycol-co-(lactic-glycolic acid)), poly(caprolactone), and 
poly(methyl) methacrylate, are frequently used for the 
manufacture of nanoparticles intended for drug delivery. Of 
these, PLA and PLGA have been approved for human use 
by the Food and Drug Administration (FDA). A wide range 
of drugs of different hydrophilicity or hydrophobicity can 
be incorporated into these polymers, and their release char-
acteristics can be tailored to meet dosing requirements. The 
performance of the polymer can be adapted to the intended 
application by controlling the molecular weight or copolymer 
composition which influences properties such as degradation 
rate, thermal sensitivity, and pH sensitivity. These polymers 
have the capability to sustain drug release for several weeks. 
Drug loading is generally achieved by encapsulation, entrap-
ment, or dissolution/dispersion. The biodegradable and 
biocompatible properties of polymeric nanoparticles make 
them very attractive candidates for drug delivery, tissue 
engineering, and biomedical applications.
There have been numerous studies over the past 18 years 
evaluating the use of various polymeric nanoparticles for 
the delivery of antiretrovirals. Antiretroviral drugs whose 
mechanism of action requires that the drug reach target 
cells must cross the mucosal epithelial barrier to exert their 
effect when administered by noninvasive routes such as oral, 
vaginal, or rectal delivery. Nanoparticles provide one strategy 
to traverse this mucosal barrier. In a study conducted by Ham 
et al, PLGA nanoparticles were used for vaginal delivery of 
PSC-RANTES, a CCR5 chemokine receptor inhibitor.22 In 
these studies, PSC-RANTES was encapsulated into PLGA 
nanoparticles via a double-emulsion, solvent-evaporation 
method. The nanoparticle system was produced to protect the 
active agent from the vaginal environment, and facilitate drug 
penetration into the vaginal and ectocervical tissue, allowing 
the drug to reach HIV target cells. The uptake of encapsulated 
PSC-RANTES by excised human ectocervical tissue as evalu-
ated in an ex vivo model was 4.8 times greater than nonen-
capsulated PSC-RANTES during a four-hour exposure time. 
Another application of this type of nanocarrier was demon-
strated by Dembri et al.40 This study involved the preparation 
of poly(isohexyl cyanate) nanoparticles of zidovudine for the 
purpose of targeting the lymphoid   tissue in the gastrointestinal 
tract. Use of this carrier system, when compared with aqueous 
drug solution, resulted in drug levels in the Peyer’s patches 
being four times higher with the encapsulated drug form. In 
a separate study, Lobenberg et al formulated polyhexylcy-
anoacrylate nanoparticles for the delivery of zidovudine.41 In 
vivo studies in rodents demonstrated higher zidovudine levels 
in the body with the encapsulated drug compared with free 
drug solution after oral administration. However, when oral 
delivery of the nanoparticles was compared with intravenous International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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administration using radioluminography, much of the orally 
administered nanoparticles were found to remain in the gas-
trointestinal tract.
Mucus, a dynamic layer present on the surface of the 
mucosal epithelium, is a major barrier for the delivery of 
antiretroviral drugs via noninvasive routes. Antiretroviral 
drugs must pass through mucus layers that may be up to a few 
hundred microns thick to reach the underlying epithelium and 
avoid clearance.42 Mucoadhesive nanoparticles can reduce the 
clearance of antiretroviral drugs from these sites and ensure 
their prolonged retention, resulting in improved absorption of 
poorly absorbable drugs. Several polymers, such as poloxam-
ers, pectins, chitosans, polyacrylates, and their derivatives, 
have been used to impart mucoadhesive properties to the 
nanoparticles by surface coating.17,43,44 In spite of extensive 
research on mucoadhesive nanoparticles for improving drug 
targeting to or through mucosal surfaces, several drawbacks 
limit their applications. The mucus turnover rate, influenced 
by a variety of factors including mucosal site, physiologic 
conditions, and presence of irritants affects the residence 
time of mucoadhesive nanoparticles.17,45 The second major 
limitation is that the mucoadhesive nanoparticles interact with 
and adhere to mucus and, hence, may be unable to reach the 
underlying epithelium or subepithelial tissues, making them 
inefficient as intracellular delivery systems.46
Mucus-penetrating nanoparticles seem to be a better option 
for overcoming the mucosal barriers. Surface properties, such 
as net charge and hydrophilicity of the nanoparticles, play a 
crucial role in their ability to penetrate the mucus and reach 
the underlying epithelium.46 Mucus is negatively charged 
due to the carboxyl and sulfate groups present on the mucin 
proteoglycans. Mucus has high densities of hydrophobic 
domains which entrap foreign materials by forming polyva-
lent, low-affinity, adhesive interactions.47,48 These interactions 
pose a challenge, particularly in the design of polymeric 
nanoparticles, because most of the polymers used for this 
purpose are either hydrophobic or have a net charge. Mimick-
ing viral surface properties may provide a way to enhance the 
diffusion of nanoparticles through mucus. Viruses capable of 
rapid transport in mucus possess hydrophilic surfaces that are 
densely coated equally with positive and negative charges, 
creating a net-neutral shell that minimizes hydrophobic and 
electrostatic adhesive interactions.46,48 Successful engineering 
of neutral surfaces with such high densities of cationic and 
anionic charges, as in the case with viral proteins, has not 
been reported so far. Nanoparticles with hydrophobic groups 
which were masked from mucus interaction by covalently 
linked polyethylene glycol (PEG) moieties were designed 
by Lai et al.49 Surface modification improved the transport 
rates by several orders of magnitude. The nanoparticles with 
neutral surfaces were transported faster through human mucus 
compared with unmodified nanoparticles. The rate of transport 
was found to be dependent on nanoparticle size, density of 
surface   coverage, and PEG molecular weight. Higher surface 
  density and lower molecular weight of PEG resulted in better 
transport of the nanoparticles through mucus.
Lymphoid tissues such as lymph nodes, spleen, and 
  gut-associated lymphoid tissue constitute major sanctuary 
sites for HIV . Approximately 99% of HIV replication occurs 
in activated and productively infected CD4+ T cells of the 
blood and lymphoid tissues, primarily the lymph nodes. 
However, the viral load of lymphoid tissues is greater than 
the   circulating blood, because only 2% of the lymphocytes 
are in the circulation at a given time, with the remaining 
being present in the lymphoid tissues, especially in lymph 
nodes.38 Lymph nodes are the sites of T cell activation and 
differentiation. They harbor a large number of T cells, 
antigen-presenting dendritic cells, and short-lived monocytes 
and macrophages. Hence, targeting antiretroviral drugs to 
the lymphoid tissues might help in better management of 
the viral infection compared with reduction of systemic 
viral load. Nanoparticles targeting macrophages and other 
cells of the mononuclear phagocytic system can be used 
to deliver antiretroviral drugs to the lymphoid tissues. The 
focus of the majority of the studies dealing with   antiretroviral 
  nanoparticles involves targeting the mononuclear phagocytic 
system, because these cells are responsible for harboring and 
dissemination of HIV virus to other anatomic sanctuary sites 
in the body, including lymph nodes. A host of   published stud-
ies in this area demonstrate the superior ability of antiretrovi-
ral nanoparticles to deliver their payload to macrophages and 
monocytes in vitro. One example of the work in this area is the 
PLGA nanoparticles containing multiple antiretroviral drugs 
(ritonavir, lopinavir, and efavirenz) which were fabricated by 
Destache et al using a multiple emulsion solvent evaporation 
technique.50 The encapsulated antiretrovirals were detected 
intracellularly in peripheral blood mononuclear cells in vitro 
after 28 days. On the contrary, unencapsulated antiretrovirals 
could not be detected after two days. Lobenberg et al studied 
the distribution of zidovudine-loaded poly(isohexyl cyanate) 
nanoparticles in vivo in rats.41 These studies revealed that 
encapsulation resulted in a higher concentration of drug in 
the cells of the reticuloendothelial system.
Nanoparticle surface modification can alter biodis-
tribution and circulation patterns. Shah and Amiji fab-
ricated poly(epsilon-caprolactone) nanoparticles loaded International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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with   saquinavir for targeting the phagocytic mononuclear 
  system.51 The surface of the nanoparticles was modified 
with poly(ethylene oxide) to prevent aggregation of the 
nanoparticles.   Intracellular drug concentrations were found 
to be higher with encapsulated saquinavir compared with 
free drug solution. However, these studies did not include 
a performance comparison of the surface-modified versus 
surface-unmodified nanoparticles. Mainardes et al studied 
the effect of surface modification in a methodical manner 
using zidovudine-loaded hydrophobic polylactide (PLA) and 
surface hydrophilic PEG nanoparticles.52 The concentration-
  dependent effects of PEG, used to modify the PLA nanopar-
ticle surfaces, were studied. According to these studies, the 
uptake of zidovudine by macrophages and polymorphonuclear 
leucocytes was higher with unmodified PLA nanoparticles 
than with PEG-modified PLA nanoparticles. PEG did not 
prevent the phagocytosis completely, even at higher concen-
trations, indicating a concentration-dependent steric effect.
The CNS is the most important HIV reservoir site. 
  However this site offers limited access to drugs and drug 
delivery systems. HIV primarily infects the microglial cells of 
the brain and causes extensive neuronal damage, particularly 
in the frontal cortex, ultimately leading to dementia.15 Antiret-
roviral drug transport across the BBB is essential to decrease 
or eradicate viral load. The BBB inhibits the transport of anti-
retroviral drugs to the brain by the presence of tight endothelial 
cell junctions and efflux transporters such as P-glycoprotein, 
multidrug resistance protein, and multispecific organic anion 
transporters.20,35 Nanoparticles are a means to overcome this 
barrier because they can cross the BBB by endocytosis/
phagocytosis and can then release drug intracellularly. Kuo 
initially reported the loading of stavudine, a nucleoside analog 
reverse transcriptase inhibitor, into polybutylcyanoacrylate 
(PBCA) and methylmethacrylate-sulfopropylmethacrylate 
(MMA-SPM) nanoparticles for brain targeting.53 By using 
an in vitro brain microvascular endothelial cell model, Kuo 
and Chen further evaluated the effect of size of PBCA and 
MMA-SPM nanoparticles on the permeability of two reverse 
transcriptase inhibitors (zidovudine and lamivudine) across 
the BBB.26 The permeability of these drugs across the BBB 
was found to be inversely proportional to nanoparticle size. 
The permeability of zidovudine and lamivudine was 8–20-fold 
higher and 10–18-fold higher, respectively, with PBCA 
nanoparticles, whereas the   MMA-SPM nanoparticles led 
to a 100% increase in the BBB permeability of both drugs. 
In a subsequent report, Kuo and Su studied the transport 
of stavudine, delavirdine, and saquinavir across the BBB 
when delivered as PBCA and MMA-SPM nanoparticles.54 
The results revealed that the permeability of all three drugs 
increased about 12–16-fold with PBCA nanoparticles and 
3–7-fold with MMA-SPM nanoparticles. In a further exten-
sion of their studies on nanoparticles, Kuo and Kuo studied 
the influence of electromagnetic field on the transport of 
antiretroviral nanoparticles across the BBB. The permeability 
of saquinavir-loaded PBCA and MMA-SPM nanoparticles 
across the BBB was enhanced significantly by the application 
of an electromagnetic field. Larger frequency, modulation or 
depth of amplitude modulation, or modulation or deviation 
of frequency modulation, resulted in greater permeability of 
the nanoparticles.55
Inorganic nanoparticles
Inorganic materials like gold, silver, iron, titanium, copper, 
silica, and zinc oxide have been fabricated as nanoparticles 
for several pharmaceutical applications, including cancer 
therapeutics,56 cellular and biomolecular labels,57 and bio-
sensors.58 Nanoparticles of noble metals like gold, silver, 
and platinum have been synthesized using a wide variety of 
methods such as bioreduction, hard template, and solution 
phase syntheses.59–61 Silver nanoparticles have received con-
siderable attention as antimicrobial agents because they have 
been shown to be effective as antibacterial62 and antiviral63,64 
agents. Antimicrobial effectiveness was shown for both Gram 
positive and Gram negative bacteria.62,65 Antiviral activity of 
silver nanoparticles has been demonstrated against several 
types of viruses, including hepatitis B, herpes simplex virus, 
respiratory syncytial virus, and monkey pox virus.63,66–68 
Recently, several studies have demonstrated their antiviral 
activity against HIV-1 in vitro.64,69,70 Silver nanoparticles were 
shown to be effective against a wide range of HIV-1 strains 
in vitro, including laboratory strains, clinical isolates, M and 
T tropic strains, and resistant strains.70 The therapeutic index 
of silver nanoparticles was found to be 12 times higher than 
that of silver ions used as silver nitrate and silver sulfadiazine 
salts, indicating that higher antiviral efficiency was specific to 
silver nanoparticles.70 Silver nanoparticles act as viral entry 
inhibitors by binding to gp120 and thus preventing CD4-
mediated viral membrane fusion to host cells and subsequent 
infectivity.69,70 They are also found to inhibit post-entry stages 
of HIV-1,70 indicating that silver nanoparticles act at multiple 
stages of the HIV life cycle. This would result in reduced risk 
for the development of viral resistance to silver nanoparticles. 
However, the in vivo antiviral activity of silver nanoparticles 
against HIV-1 has yet to be demonstrated.
Another inorganic nanoparticulate system evaluated for 
antiretroviral drug delivery consists of gold   nanoparticles. International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Bowman et al used small molecule-conjugated gold 
  nanoparticles as anti-HIV agents.71 SDC-1721, a fragment 
of the potent HIV inhibitor TAK-779, was synthesized and 
conjugated to gold nanoparticles. Free SDC-1721 had no 
inhibitory activity in HIV infection. However, antiretroviral 
activity comparable with TAK-779 was observed when SDC-
1721 was conjugated to gold nanoparticles. Gold nanopar-
ticles transformed the biologically inactive SDC-1721 into a 
multivalent conjugate that effectively inhibited HIV-1 fusion 
to human T lymphocytes.
One drawback to the use of inorganic nanoparticles is 
potential toxicity. Toxicity of inorganic nanoparticles must be 
studied carefully before they can be clinically applied. Sev-
eral studies have demonstrated the cytotoxic effects of these 
inorganic nanoparticles.72–75 In studies evaluating acute toxic-
ity, silver nanoparticles were found to be highly cytotoxic to 
mammalian cells based on the assessment of mitochondrial 
function, membrane leakage of lactate   dehydrogenase, and 
abnormal cell morphologies.72,75 Toxicity studies conducted 
on human lung fibroblast cells (IMR-90) and human glio-
blastoma cells (U 251) revealed the generation of reactive 
oxygen species by cells exposed to silver nanoparticles.73 
DNA damage and cell cycle arrest in the G(2) or M phase 
was observed. In studies by Kawata et al using HepG2 human 
hepatoma cells, subacute exposure to silver nanoparticles 
resulted in abnormal cell morphology and increased cell 
proliferation possibly due to hormesis, ie, a stimulatory effect 
exhibited by low levels of potentially toxic agents.74 The inci-
dence of micronuclei formation, indicative of chromosomal 
aberrations or breakage, was significantly higher in cells 
exposed to subacute levels of silver nanoparticles. Studies 
on rodents showed that silver nanoparticles accumulated in 
various organs including the lungs, kidneys, brain, liver, and 
testes.76 Furthermore, DNA microarray analysis indicated an 
induction of a large number of genes, particularly, stress-
associated genes coding metallothionine and heat shock 
protein.74 Similar studies on other inorganic nanoparticles, 
including gold and titanium dioxide, have indicated toxicity 
via DNA damage and   cellular apoptosis.77,78
Dendrimers
Dendrimers are a versatile class of regularly-branched mac-
romolecules with unique structural and topologic features. 
Small size (typically less than 100 nm), narrow molecular 
weight distribution, and relative ease of incorporation 
of targeting ligands make them attractive candidates for 
drug delivery. Dendrimers have minimal polydispersity 
and high functionality. Similar to polymers, they are 
obtained by attaching several monomeric units, but unlike 
the   conventional polymers, they have a highly branched 
three-dimensional architecture. Dendrimers are charac-
terized by the presence of three different topologic sites, 
ie, a polyfunctional core, interior layers, and multivalent 
  surface.36 The polyfunctional core, surrounded by extensive 
branching, has the ability to encapsulate several chemical 
moieties. Ammonia and ethylene diamine are two examples 
of core-synthesizing materials. The core may be surrounded 
by several layers of highly branched repeating units, such 
as polyethers, porphyrins, polyamidoamines, polyphenyls, 
and polyamino acids. The properties of the dendrimer are 
predominantly based on the multivalent surface, which has 
several functional groups that interact with the external 
environment. The precise physicochemical properties of 
dendrimers can be controlled during synthesis by controlling 
the core groups, the extent of branching, and the nature and/or 
number of functional groups on the surface.79,80 Dendrimers 
can not only act as carriers of antiretroviral agents, but can 
also themselves act as antiretrovirals. Dendrimers with inher-
ent antiretroviral activity can be synthesized by incorporating 
certain functional groups on their surface that can interfere 
with the binding of the virus to the cell. A diverse array of 
dendrimers with various patterns of biologic activity can be 
synthesized by making subtle changes, such as the type of 
initiator, branching unit type, dendrimer generation, linker, 
and surfaces.81 The inherent antiviral activity of dendrimers 
has been demonstrated against influenza virus,82 respiratory 
syncytial virus,83 and HIV84 in vitro. These dendrimers pri-
marily act by blocking viral fusion to target cells and thus 
act as entry inhibitors in the early stages of viral infection, 
although secondary mechanisms of action at later stages of 
the viral life cycle have been reported.36,81
Water-soluble dendrimers can be used as efficient car-
riers of antiretroviral agents which can be entrapped in the 
dendrimer architecture. The antiretrovirals or their prodrugs 
can also be grafted covalently onto the surface of the den-
drimers, either alone or in conjunction with other molecules, 
such as targeting moieties and fluorescent tags. Multivalent 
dendrimeric systems have been of much interest in the field 
of antiviral therapy. Dutta et al developed efavirenz-loaded, 
tuftsin-conjugated poly(propyleneimine) dendrimers for 
targeted delivery to macrophages.85 Tuftsin is a natural mac-
rophage activator tetrapeptide (Thr-Lys-Pro-Arg) which binds 
specifically to mononuclear phagocytic cells and enhances 
their phagocytic activity. These multivalent dendrimers 
showed reduced cytotoxicity compared with   nonconjugated 
poly(propyleneimine) dendrimers in vitro. The free amino International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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groups present on poly(propyleneimine)   dendrimers are 
responsible for their cytotoxicity.   Conjugation of tuftsin to 
poly(propyleneimine) dendrimers reduced the cytotoxic-
ity of these dendrimers, possibly by shielding the positive 
charges and thus preventing their interaction with cell 
membranes. The tuftsin-conjugated poly(propyleneimine) 
dendrimers showed enhanced cellular uptake by mononuclear 
  phagocytic cells and greater anti-HIV activity in vitro. The 
same research group loaded lamivudine into mannose-capped 
poly(propyleneimine) dendrimers and observed a significant 
increase in antiretroviral activity, cellular uptake, and reduced 
cytotoxicity.86 The mannose conjugation enabled the targeted 
delivery of the lamivudine-loaded dendrimers to macrophages 
containing lectin receptors on their surface. Dendrimers have 
been used to transfect silencing RNA (siRNA) to reduce HIV 
infection in vitro. Amino-terminated carbosilane dendrim-
ers were used to protect and transfer siRNA to lymphocytes 
in vitro.24 These dendrimers bind to siRNA via electrostatic 
interactions and protect it from RNase degradation.
The V3 loop region of viral gp120 interacts with glyco-
lipids, such as galactosylceramide, on the host cell for cell 
attachment and subsequent cell entry.87,88 Anionic polymers 
and dendrimers through ionic interactions with the V3 loop 
of gp120 interfere with viral-host cell interactions.89,90 One 
such anionic dendrimer is SPL7013, a poly-L-lysine den-
drimer with naphthalene sulfonic acid terminations. It has 
a divalent benzhydrylamine amide of L-lysine as the core. 
Efficacy studies with 5% w/w SPL7013 as an aqueous gel 
showed that a single intravaginal dose of the formulation 
protected pig-tailed macaques from intravaginal simian-
human immunodeficiency virus infection.91 VivaGel® is an 
aqueous-based polyacrylic acid gel containing SPL7013 
buffered to physiologic pH. VivaGel is the first dendrimer-
based drug application that has been submitted to the US 
FDA as an investigational new drug.92 Phase I clinical trials 
showed no systemic absorption following intravaginal dos-
ing, indicative of the desired retention in the vaginal lumen. 
The safety profile of VivaGel was comparable with placebo 
gel, indicating no toxicity.93 The antiretroviral activity of 
sulfated oligosaccharides is very low.94 However, sulfated 
oligosaccharides when attached to a dendrimer show high 
antiretroviral activity due to cluster effects.95 Recently, 
Han et al have developed oligosaccharide-based polylysine 
dendrimers with sulfated cellobiose.96 These were shown to 
possess high anti-HIV activity, almost equivalent to dide-
oxycytidine, and low cytotoxicity.
Multivalent phosphorus-containing catanionic dendrim-
ers with galactosylceramide analogues were developed by 
Blanzat et al.97 The influence of the multifunctional core, the 
alkyl chains, and the surface properties of the dendrimers 
on their stability, cytotoxicity, and antiretroviral properties 
were reported by the same group in subsequent studies.98,99 
Galactosylceramide has a high affinity for the V3 loop of the 
gp120 viral envelope protein of HIV-1, and subsequently pre-
vents viral fusion to the host cell membrane, thus acting as an 
entry inhibitor. Although the galactosylceramide dendrimers 
showed good antiretroviral activity, a low therapeutic index 
associated with cytotoxicity is one of the issues that need 
to be addressed before these can be considered promising 
antiretroviral agents.
Solid lipid nanoparticles
Solid lipid nanoparticles (SLNs) are made of fatty acids that 
are solid or semisolid at room temperature. Lipids with high 
melting point such as stearic acid, glyceryl monostearate, 
cetyl palmitate, and hydrogenated cocoglycerides and emul-
sifiers, such as phosphatidylcholine, lecithins, polysorbates, 
poloxamers, bile salts, and fatty acid coesters are used to 
prepare and stabilize the SLNs, respectively. Sustained drug 
release and site specificity for drug delivery can be achieved 
by altering the properties of SLNs, such as their lipid compo-
sition, size, and surface charge. SLNs can be manufactured to 
release drug in response to an external trigger, such as pH and 
temperature. This delivery system offers several advantages 
such as relative ease of production, sterilization, and scale-up, 
avoidance of the use of organic solvents, low-cost excipients, 
and biocompatibility. Compared with nanoemulsions which 
are liquid lipid encapsulations of the drug, SLNs containing 
the lipid in the solid state impart greater drug stability and 
better control over drug-release kinetics.
Zidovudine palmitate-loaded SLNs prepared by Heiati 
et al are the first reported antiretroviral SLNs.100 Trilaurin 
was used as the lipid core in these systems. Dipalmitoyl 
phosphatidylcholine alone or in combination with dimyris-
toylphosphatidylglycerol was used as a coating. The resultant 
SLNs were either neutral or negatively charged. Drug loading 
was dependent on the outer phospholipid coat, with higher 
phospholipid content resulting in greater drug incorporation. 
In a subsequent study by the same group, the surfaces of these 
SLNs were modified by the attachment of PEG moieties, thus 
improving the plasma circulation half-life of the drug.101
SLNs have been widely used to overcome biological 
barriers, such as the BBB and blood-cerebrospinal fluid 
barrier. The use of SLNs for drug delivery to the brain was 
first proposed by Yang et al and Zara et al independently 
in the late 1990s in their studies of the pharmacokinetics International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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of two anticancer agents, camptothecin and doxorubicin, 
respectively.102,103 Accumulation of the drug in the brain 
was observed after both oral and systemic administration 
of drug-loaded SLNs in rats. Since then, several studies 
were conducted on the ability of SLNs to improve the brain 
delivery of drugs. Kuo and Su prepared SLNs loaded with 
stavudine, delavirdine, and saquinavir independently and 
evaluated their ability to cross the BBB in vitro using human 
brain microvascular endothelial cells.54 The entrapment 
efficiency of the drugs followed their lipophilicity, with the 
more lipophilic saquinavir having the maximum entrapment 
efficiency, indicating the better suitability of SLNs to more 
lipophilic drugs. The permeability of the drugs was improved 
4–11-fold when incorporated into SLNs. Chattopadhyay et al 
used SLNs made of stearic acid for delivery to the brain of 
atazanavir, a highly lipophilic antiviral protease inhibitor.104 
In this study the SLNs were prepared by a microemulsion 
technique using Pluronic F68 as an emulsifier. In vitro studies 
using hCMEC/D3, a human brain microvessel endothelial 
cell line, showed a higher uptake of the drug when delivered 
in SLN form, as compared with free atazanavir. Atazanavir 
is a substrate for the adenosine triphosphate-binding cas-
sette membrane-associated drug efflux transporters, such 
as P-glycoprotein. The activity of these efflux transporters 
results in lower intracellular accumulation of atazanavir. The 
authors hypothesize that SLNs circumvent P-glycoprotein-
mediated efflux and mask the drug from the membrane 
bound P-glycoprotein efflux transporter, thus facilitating its 
intracellular accumulation.
Several surface modifications were studied to improve 
the targeting ability of SLNs further. PEG moieties attached 
to the surface of SLNs impart stealth characteristics to the 
SLNs and improve their delivery to brain.105,106 Surface 
charge modification is another approach that has been used 
to improve the targeted drug delivery of SLNs. Positively 
charged SLNs are found to deliver higher amounts of drugs 
to the brain than uncharged or negatively charged SLNs. Kuo 
and Chen prepared cationic SLNs loaded with the lipophilic 
protease inhibitor, saquinavir.107 A blend of the nonionic lip-
ids Compritol ATO 888 and cacao butter were used as core 
lipids. Stearylamine and dioctadecyldimethyl ammonium 
bromide comprised the peripheral cationic lipids. Polysorbate 
80 was used as an SLN emulsifier/stabilizer. However, this 
study did not include any in vitro or in vivo demonstration of 
their improved ability to deliver the drug to the target sites. 
The modification of surface charge to enhance drug delivery 
to the CNS must be applied with caution because positively 
charged SLNs and high amounts of negatively charged SLNs 
were shown to increase the cortical cerebrovascular volume 
of rats significantly in situ in brain perfusion experiments, 
indicating a compromise in the integrity of the BBB.108
Liposomes
Liposomes are lipid vesicles consisting of phospho-
lipid   bilayers. They have an aqueous core which can be 
used to encapsulate hydrophilic drugs while hydrophobic and 
amphiphilic drugs can be solubilized within the phospholipid 
bilayers. Liposomes are of three types, ie, small unilamel-
lar vesicles, large unilamellar vesicles, and multilamellar 
vesicles. Liposomes in their native form are taken up by the 
reticuloendothelial system and are quickly cleared from the 
circulation. This property was exploited for the macrophage 
delivery of antiretrovirals. Phillips et al used a liposomal drug 
delivery system to deliver zidovudine to macrophages.109 
Zidovudine, which is an amphiphilic compound, showed 
low entrapment and significant leakage from the liposomal 
vesicles over time, due to its tendency to partition between 
the aqueous core and the lipid bilayer.110 Jin et al studied the 
incorporation of the myristate prodrug of zidovudine in the 
liposomal formulation to target macrophages.27 The prodrug, 
being lipophilic, resulted in greater entrapment efficiency and 
a longer half-life, as demonstrated in vivo in rats.
Liposomes rendered elastic by the incorporation of an 
edge activator in the lipid bilayer were studied as transder-
mal delivery agents for antiretroviral drugs.111,112 Another 
approach used to improve the transdermal flux of liposomes 
is incorporation of ethanol into the liposomes to form etho-
somes. Several in vitro and ex vivo studies were conducted by 
Jain et al incorporating antiretroviral drugs such as acyclovir, 
indinavir, zidovudine, and lamivudine into these modified 
liposomal systems.111–116 The in vitro studies and ex vivo 
studies using human cadaver and rodent skin models showed 
greater transdermal flux of antiretroviral drugs with the 
modified liposomes compared with conventional liposomes, 
ethanolic solutions, or hydroethanolic solutions.
Liposomes are quickly phagocytosed by macrophages 
upon entering the systemic circulation. To prolong their 
circulation time and improve their bioavailability to infected 
cells as well as macrophages, liposomal surfaces are coated 
with hydrophilic polymers, such as PEG.112,117 Approaches 
involving more specific targeting of liposomes were pursued 
to improve antiretroviral delivery further. Flasher et al used 
liposomes coupled to sCD4, a soluble form of the natural 
host ligand of gp120, to target HIV-infected cells.118,119 
CD4-derived peptides were studied instead of sCD4 for the 
targeted delivery of liposomes due to the relative ease of International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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their production and their nonimmunogenicity.120 Targeting 
moieties based on antibodies have been studied by several 
investigators for liposomal delivery of antiretrovirals.121–123 
Clayton et al used a human monoclonal immunoglobulin G1κ 
(IgG1κ) antibody, monoclonal antibody F105, that specifi-
cally binds to the viral gp120 as a targeting moiety on the 
pegylated liposomes.122 The antiretroviral protease inhibitor, 
PI1, a substituted benzimidazole sulfonamide encapsulated 
into these anti-HIV liposomes, was shown to be selectively 
delivered to HIV-infected cells. The inhibitory effect of the 
targeted PI1 on viral replication was greater than that of a 
comparable concentration of free or nontargeted drug.
Other studies evaluated the use of mannose and galactose 
as targeting moieties on liposomes.124–126 These moieties 
bind to lectin receptors present on the surface of cells of 
the mononuclear phagocyte system. Stavudine loaded into 
  mannosylated and galactosylated liposomes exhibited greater 
cellular uptake by cells of the mononuclear phagocytic 
system and greater accumulation in organs of the reticu-
loendothelial system such as the liver, spleen, and lungs of 
Sprague Dawley rats compared with free drug solution or 
nonmodified liposomes.124,125
There are certain disadvantages to liposomes that limit 
their use in antiretroviral drug delivery. The hydrophilic 
drug-loading capacity of liposomes is very limited due to the 
small volume of the core (approximately 15 µL).20 Long-term 
physical and biologic stability is another challenging issue 
in the design of liposomal delivery systems which precludes 
their use for sustained drug delivery applications.
Miscellaneous
Cyclodextrins are a group of naturally occurring cyclic oli-
gosaccharides composed of (1,4)-linked α-D-glucopyranose 
units. Topologically, cyclodextrins form a torus with a 
hydrophobic interior and a hydrophilic exterior. This allows 
cyclodextrins to act as host molecules that form inclusion 
complexes with hydrophobic guest molecules. Thus, cyclo-
dextrin complexes can be used to enhance the solubility of 
lipophilic antiretroviral drugs, as well as to protect them 
from external degradation. Several classes of cyclodex-
trins, including β-cyclodextrin, methyl-β-cyclodextrin, and 
2-hydroxypropyl-β-cyclodextrin, were studied for their abil-
ity to improve the solubility of the hydrophobic   antiretroviral 
agents, efavirenz and UC781.127,128 Hydroxypropyl-β-
cyclodextrin and methyl-β-cyclodextrin complexed to 
efavirenz showed faster in vitro dissolution rate profiles 
compared with free efavirenz.127 The in vitro inhibition 
demonstrated by a UC781:2-hydroxypropyl-β-cyclodextrin 
  complex, as measured by HIV-1 reverse   transcriptase 
  inhibitory assay, was found to be enhanced by more than 
30-fold when compared with noncomplexed UC781.128 In 
a separate study, Buchanan et al used hydroxylbutenyl-β-
cyclodextrin to improve the bioavailability of saquinavir.129 
The resulting complexes were found to have increased 
aqueous solubility and bioavailability in vivo as studied in 
Wistar-Hannover rats. The oral bioavailability of saquinavir 
was enhanced approximately nine-fold when administered 
as a complex compared with saquinavir mesylate.
Polymeric micelles composed of block copolymers have 
been utilized for improving aqueous solubility, membrane 
permeability, and site-specific delivery of several drug 
  moieties. They have a vesicular or core shell structure similar 
to surfactant-based micelles, but self-associate at much lower 
concentrations, typically in the 0.1–1 µM range compared 
with 0.1–1 mM for surfactant-based micelles.130 The core of 
the micelles is usually derived from polymers, such as pro-
pylene oxide, aspartic acid, L-lysine, and caprolactone which 
constitute the hydrophobic block. The shell is composed of 
a hydrophilic block derived from polymers such as polyeth-
yleneimine, polyvinylalcohol, and polyethyleneoxide.21,131 
Depending on the polarity of the drug, it may be entrapped 
in the core, shell, or at the interface between the two. Block 
copolymers of poly(ethylene)oxide-polypropylene oxide, 
also known as Pluronics, are FDA-approved and are the most 
common block copolymers for the preparation of polymeric 
micelles used for drug delivery and targeting. Pluronics of 
intermediate length and hydrophobicity, such as P85, inhibit 
the efflux transporters, eg, adenosine triphosphate-binding 
cassette transporters that have been shown to reduce the 
oral bioavailability and CNS permeability of several classes 
of antiretroviral drugs.132 Coadministration of antiretrovi-
ral drugs such as zidovudine, nelfinavir, and lamivudine 
with P85 has been shown to enhance their permeability 
in vitro in bovine brain microvessel endothelial cells and 
macrophages.132,133 The enhancement of efficacy of antiret-
rovirals upon co-administration with P85 was demonstrated 
in vivo in a severe combined immunodeficiency mouse 
model of HIV-1 encephalitis.134 Ligands specific for the 
type of receptors present on the HIV-infected cells, such as 
galactose and lactose units, that specifically interact with 
lectin receptors on the HIV viral reservoir sites, such as 
T lymphocytes, macrophages, and dendritic cells, can be 
attached to the surface of the polymeric micelles to achieve 
drug targeting.21,135 However, the biological stability of 
the polymeric micelles remains an issue, limiting their use 
for sustained drug delivery applications.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Nanoemulsions are kinetically stable transparent or 
  translucent heterogeneous liquid dispersions which can 
exist as water-in-oil (w/o) or oil-in-water (o/w) forms. The 
internal phase liquid is reduced to droplets of #400 nm.15 
  Nanoemulsions are thermodynamically stable with very low 
surface tension, due to their small droplet size.136 The properties 
of the internal phase, including stability, are dependent on the 
composition of the surfactant present at the droplet interface. 
The choice of oil and surfactant will influence the in vitro as 
well as in vivo stability, transport, and release characteristics 
of the nanoemulsion formulation. Vyas et al used an o/w 
nanoemulsion to improve the oral bioavailability and brain 
delivery of saquinavir.137 The rate and extent of oral absorption 
followed by brain localization of saquinavir in BALB/c mice 
was found to be greater with saquinavir-loaded nanoemulsions 
than with an aqueous suspension of the drug.
Cell-based nanoformulations seem to be an efficient and 
promising drug delivery approach, especially to the viral 
sanctuary sites typically inaccessible to antiretroviral drugs. 
Dou et al explored a novel macrophage-based indinavir nano-
formulation for the treatment of HIV infection.138–140 They 
postulated that macrophages, the principal reservoir sites 
responsible for dissemination of HIV , can enter into tissues 
and anatomic sites with limited access to antiretroviral drugs 
and, hence, they could be used as transporters for antiretro-
viral drugs themselves. In their study, indinavir-loaded lipid 
nanoparticles prepared with Lipoid E80 were incorporated 
into murine bone marrow-derived macrophages. These 
nanoparticulate drug-loaded macrophages were studied for 
their tissue distribution and disease outcomes with immune-
competent and HIV-1-infected humanized immune-deficient 
mice, respectively.138 Sustained drug levels far exceeding 
therapeutic concentrations accompanied by reduced viral 
load were achieved in serum and locally in HIV target tissues 
including lung, liver, and spleen in HIV-1 infected humanized 
immune-deficient mice for two weeks.138 In a later study in 
mice with HIV-1 encephalitis, indinavir nanoparticles were 
detected in the brain, especially in the regions with active 
astrogliosis, microgliosis, and neuronal loss, indicating 
the ability of these nanoformulations to overcome the BBB.140 
The presence of these indinavir nanoparticles in the afore-
mentioned brain subregions was associated with reduced 
HIV-1 replication. In separate studies, cell-based antiret-
roviral nanoformulations with human monocyte-derived 
macrophages were developed and studied for their properties 
in vitro.139,141 Initially, lipid nanoparticles of indinavir were 
packaged into the human macrophages.123 Later, a combi-
nation of indinavir-, ritonavir-, and   efavirenz-loaded lipid 
nanoparticles were packaged into the human macrophages.141 
The antiretroviral nanoparticles taken up into the cytoplasmic 
vesicles of the macrophages released the drugs for two weeks. 
Dose-dependent reduction of viral replication and HIV-1 p24 
antigen were observed.
Conclusion and future perspectives
HIV infection has reached pandemic levels. Due to the com-
plexities of both the HIV infection cycle and the   targets for 
delivery of drugs intended to prevent or treat this disease, 
more efficient drug delivery systems are needed. Various 
forms of nanocarriers have been studied as a means to 
enhance the effective delivery of antiretroviral drugs for 
HIV prevention and therapy. Among these are nanoparticles 
(polymeric, inorganic, and solid lipid), liposomes, polymeric 
micelles, dendrimers, cyclodextrins, and cell-based nanofor-
mulations. Such drug delivery systems have shown promise 
in various models ranging from in vitro to in vivo. It has been 
shown that the application of nanocarrier systems for delivery 
of antiretroviral drugs can achieve more efficient distribution, 
provide a mechanism to cross the BBB and other tissue or 
cell barriers to delivery, and provide a means to overcome 
innate barriers to delivery, such as mucus. Although a num-
ber of publications in this area have been presented within 
the scope of this review, work is still limited and must be 
expanded to elucidate fully the potential for application of 
nanocarrier delivery systems for the design of more efficient 
antiretroviral drug products.
As more information about HIV infection and lifecycle 
becomes available, nanocarriers with better surface modifiers 
for improved targeting and longer duration of action should 
become available. The majority of work done to date in the 
field of nanocarrier antiretroviral drug delivery systems 
involves the use of single antiretroviral agents. Given that it 
has been found that use of combinations of drugs can lead 
to more efficacious treatments and reduction of resistance 
profiles, studies applying nanocarriers to combined delivery 
strategies should be conducted. Further studies regarding the 
safety and efficacy profiles of the antiretroviral   nanocarriers 
must be performed. Minimal information is currently avail-
able regarding the short- and long-term toxicity of nanocar-
riers. Finally, scale-up considerations for the manufacture 
of nanocarrier systems is another issue that needs to be 
addressed in order to make the nanocarrier therapeutic 
approach feasible.
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